| Eton Pharmaceuticals to Participate at Upcoming Investor Conferences |
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, and David Krempa, Chief Business Officer, will participate in two upcoming investor conferences as follows: |
globenewswire.com |
2025-05-14 20:30:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript |
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Madison Elsaadi - B. Riley Swayampakula Ramakanth - H.C. |
seekingalpha.com |
2025-05-14 02:40:22 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates |
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.03 per share a year ago. |
zacks.com |
2025-05-13 22:20:40 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Reports First Quarter 2025 Financial Results |
DEER PARK, Ill., May 13, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 |
DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). |
globenewswire.com |
2025-05-01 20:30:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release |
Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:37 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) |
- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – |
globenewswire.com |
2025-04-28 10:50:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Out-Licenses International Rights to Increlex® |
DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out-licensing of commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. |
globenewswire.com |
2025-04-01 11:00:00 |
Czytaj oryginał (ang.) |
| CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program |
Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital adrenal insufficiency market. CROSSJECT will earn a high-single digit royalty on ETON's net sales. |
globenewswire.com |
2025-03-25 04:30:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript |
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q4 2024 Earnings Conference Call March 18, 2025 10:00 AM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Ipek Trinkaus - Chief Commercial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Madison Elsaadi - B. Riley Operator Good day, and thank you for standing by. |
seekingalpha.com |
2025-03-18 21:42:12 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates |
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago. |
zacks.com |
2025-03-18 11:00:24 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results |
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growth Closed the transformational acquisition of pediatric endocrinology biologic Increlex® and relaunched the product in January Acquired and relaunched ultra rare disease product Galzin® Licensed U.S. rights to late-stage pipeline candidate Amglidia®, further boosting the Company's pediatric endocrinology pipeline Announced positive pivotal clinical study results for ET-600; preparing for an April 2025 NDA submission Manufactured ET-400 launch inventory in preparation for a potential approval on its PDUFA goal date of May 28 Management to hold Investor Day conference call today at 10:00am ET to discuss its recent acquisitions and review its product portfolio, market opportunities, and 2025 and long-term financial outlook DEER PARK, Ill., March 18, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2024. |
globenewswire.com |
2025-03-18 08:50:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 |
- Company's patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in April 2025 - |
globenewswire.com |
2025-03-14 08:50:00 |
Czytaj oryginał (ang.) |
| Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN® |
Optime Care has expanded partnership with Eton Pharmaceuticals to serve as the SP provider for GALZIN®, an FDA-approved treatment for Wilson Disease. |
globenewswire.com |
2025-03-04 12:00:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 |
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT). |
globenewswire.com |
2025-03-04 08:50:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules |
– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and best-in-class patient support services –– Now available exclusively through Optime Care – |
globenewswire.com |
2025-03-03 08:50:00 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going |
Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2025-02-12 11:51:16 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600 |
- Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration's (FDA) Orange Book upon the product's approval – |
globenewswire.com |
2025-02-07 08:50:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400 |
DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for ET-400. The new PDUFA goal date is May 28, 2025. |
globenewswire.com |
2025-02-06 08:50:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 28th |
PBPB, BBCP, BAK, NVAX and ETON have been added to the Zacks Rank #1 (Strong Buy) List on January 28, 2024. |
zacks.com |
2025-01-28 09:21:26 |
Czytaj oryginał (ang.) |
| Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength? |
Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-01-24 07:21:02 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® |
DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired Galzin® (zinc acetate). |
globenewswire.com |
2025-01-03 08:50:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection) |
DEER PARK, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has completed its previously announced asset purchase of Increlex® (mecasermin injection) from Ipsen S.A. (“Ipsen”). Increlex® is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). |
globenewswire.com |
2024-12-20 08:50:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer |
DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). |
globenewswire.com |
2024-12-03 08:50:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension) |
DEER PARK, Ill., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired the U.S. rights to Amglidia (glyburide oral suspension, known as glibenclamide in Europe) for the treatment of neonatal diabetes mellitus from AMMTeK. |
globenewswire.com |
2024-11-25 08:50:00 |
Czytaj oryginał (ang.) |
| What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing' |
Eton Pharmaceuticals (ETON) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2024-11-18 11:50:16 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript |
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Chase Knickerbocker – Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2024-11-12 22:01:58 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results |
DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2024. |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 |
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). |
globenewswire.com |
2024-11-06 18:30:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen |
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions |
globenewswire.com |
2024-10-03 10:30:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference |
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. |
globenewswire.com |
2024-08-22 20:30:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript |
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised, this call is being recorded at the company's request. |
seekingalpha.com |
2024-08-11 12:15:27 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results |
DEER PARK, Ill., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2024. |
globenewswire.com |
2024-08-08 20:01:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 |
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). |
globenewswire.com |
2024-07-30 21:30:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution) |
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company's New Drug Application (NDA) for ET-400, a proprietary patented formulation of hydrocortisone oral solution, has been accepted by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025. |
globenewswire.com |
2024-07-15 20:05:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript |
Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript May 9, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode. |
seekingalpha.com |
2024-05-11 13:34:08 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Reports First Quarter 2024 Financial Results |
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400• Management to hold conference call today at 4:30pm ET |
globenewswire.com |
2024-05-09 20:01:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference |
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows: |
globenewswire.com |
2024-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution) |
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 - |
globenewswire.com |
2024-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 |
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). |
globenewswire.com |
2024-04-29 20:30:00 |
Czytaj oryginał (ang.) |
| Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria |
DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. rights to PKU GOLIKE® from RELIEF THERAPEUTICS Holding SA (“Relief”) (SIX: RLF, OTCQB: RLFTF, RLFTY). |
globenewswire.com |
2024-03-22 04:00:00 |
Czytaj oryginał (ang.) |